SCHEMBL16886175

SCHEMBL16886175

Nc1ncnc2c1c(-c1ccc(Oc3cc(F)cc(OCc4cccn4CCOCc4ccccc4)c3)cc1)nn2C1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 16/20 0.50
▸ LCK P06239 6/20 0.50
▸ LYN P07948 2/20 0.50
▸ NUDT14 O95848 1/20 0.49
▸ NUDT5 Q9UKK9 1/20 0.49
▸ SRC P12931 4/20 0.47
▸ KDR P35968 3/20 0.47
▸ TEK Q02763 1/20 0.47
▸ EGFR P00533 9/20 0.46
▸ ITK Q08881 3/20 0.46
▸ PIK3CD O00329 4/20 0.43
▸ ABL1 P00519 3/20 0.43
▸ HCK P08631 3/20 0.43
▸ PIK3CA P42336 3/20 0.43
▸ PIK3CB P42338 3/20 0.43
▸ PIK3CG P48736 3/20 0.43
▸ PRKDC P78527 3/20 0.43
▸ MTOR P42345 2/20 0.43
▸ EPHB4 P54760 2/20 0.43
▸ PI4KB Q9UBF8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886181 0.91 BTK (0.53) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613502 0.91 BTK (0.49) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886177 0.91 BTK (0.50) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886200 0.89 BTK (0.50) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613512 0.88 BTK (0.61) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886183 0.88 BTK (0.51) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886164 0.86 BTK (0.54) BTKLCKLYNNUDT14NUDT5
SCHEMBL19484825 0.86 BTK (0.49) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886170 0.84 BTK (0.60) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613681 0.84 BTK (0.52) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885LCK 3/4885LYN 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback